YTS109 cell is named as an intervention in 7 current clinical trials in our China register. 5 are recruiting patients now. All registered phases are Phase 1. The sponsor with the most trials is China Immunotech (Beijing) Biotechnology Co., Ltd (6). The most-studied condition is Systemic Lupus Erythematosus (SLE).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus
NCT06943937 · ClinicalTrials.gov ↗ · Lupus Nephritis (LN), Immune Thrombocytopenia (ITP)
|
Phase 1 | Recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | China |
|
A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
NCT06978647 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), Inflammatory Myopathy
|
Phase 1 | Recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | China |
|
A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
NCT07104721 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Systemic Sclerosis (SSc)
|
Phase 1 | Recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | China |
|
An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
NCT07236762 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus, Lupus Nephritis (LN), Sjogren's Syndrome
|
Phase 1 | Recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | China |
|
Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
NCT07236801 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus (SLE), Systemic Sclerosis, Sjogren's Syndrome (SS)
|
Phase 1 | Recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | China |
|
YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases
NCT07439029 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus (SLE), Diffuse Systemic Sclerosis, Idiopathic Inflammatory Myopathies (IIMs)
|
Phase 1 | Not yet open | Children's Hospital of Fudan University | China |
|
Research on YTS109 Cell in Patients With Recurrent/Refractory Autoimmune Hemolytic Anemia
NCT07453836 · ClinicalTrials.gov ↗ · Autoimmune Hemolytic Anemia
|
Phase 1 | Not yet open | China Immunotech (Beijing) Biotechnology Co., Ltd. | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Systemic Lupus Erythematosus (SLE) | 4 |
| Inflammatory Myopathy | 4 |
| Lupus Nephritis (LN) | 3 |
| Systemic Sclerosis (SSc) | 2 |
| Systemic Lupus Erythematosus | 1 |
| Sjogren's Syndrome | 1 |
| Diffuse Systemic Sclerosis | 1 |
| Idiopathic Inflammatory Myopathies (IIMs) | 1 |
| ANCA Associated Vasculitis (AAV) | 1 |
| Systemic Sclerosis | 1 |
| Sjogren's Syndrome (SS) | 1 |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 |
| Autoimmune Hemolytic Anemia | 1 |
| Immune Thrombocytopenia (ITP) | 1 |
| Lead sponsor | Trials |
|---|---|
| China Immunotech (Beijing) Biotechnology Co., Ltd. | 6 |
| Children's Hospital of Fudan University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 7 | 5 |
A trial with sites in more than one country appears in each of those registers.
7 current trials in our China register name YTS109 cell as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 5 of the 7 trials are recruiting: 5 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
China Immunotech (Beijing) Biotechnology Co., Ltd (6) and Children's Hospital of Fudan University (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how YTS109 cell works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how YTS109 cell works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists YTS109 cell (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.